Study shows value of HIV screening in virtually all health settings

December 04, 2006

Voluntary screening for HIV should be a routine part of the medical care of all adults, not just those at high risk, according to a study by researchers at the Yale School of Medicine.

The team reports in the December 5 Annals of Internal Medicine that routine HIV screening is cost-effective, even in communities where as few as two in 1,000 people have undiagnosed HIV infection.

The study provides strong support for U.S. Centers for Disease Control and Prevention guidelines issued in September 2006 that recommend routine HIV screening of all persons age 13 to 64 in all health care settings. The guidelines were based in part on findings of the study team led by A. David Paltiel, professor in the Department of Epidemiology and Public Health at the Yale School of Medicine, and the Yale School of Management.

"HIV screening delivers better value than many other diagnostic tests and treatments that physicians use routinely in daily practice, including screening for breast cancer, colorectal cancer, diabetes and hypertension," said Paltiel, who cites the roughly 300,000 Americans who do not know they are infected with HIV as the reason to make HIV screening as routine as measuring cholesterol. "Early identification of HIV saves lives."

Paltiel and his colleagues developed a mathematical model to simulate the events that occur in an HIV-infected person, including detection, treatment, medical expenses, transmitting the disease to others, and death. The model calculated the additional costs due to screening and the additional survival attributable to earlier detection. It also calculated how much life was shortened by HIV infection. The model then estimated the cost per extra year of life gained (cost-effectiveness) from HIV screening.

"The HIV epidemic is no longer confined to a handful of identifiable risk groups, yet current approaches to HIV testing still focus on the old target populations," said study co-author Kenneth Freedberg, M.D., director of HIV Outcomes Research at the Harvard Medical School, who is also affiliated with the Partners AIDS Research Center at Massachusetts General Hospital.

The authors caution that the study's findings hinge on the assumption that persons identified with HIV will be linked to state-of-the art, life-saving care. "There is no point searching for needles in haystacks if you merely plan to throw them back in," said Paltiel. "The CDC's commitment to expanded HIV screening must be accompanied by an equally bold financial commitment from the state and federal agencies that provide and pay for HIV care."
-end-
The study was supported by grants from the National Institutes of Mental Health, the National Institute of Allergy and Infectious Diseases, the National Institute on Drug Abuse, the Doris Duke Charitable Foundation and the Centers for Disease Control and Prevention.

Other authors on the study include Rochelle P. Walensky and Lauren M. Mercincavage of Massachusetts General Hospital; Bruce R. Schackman of Weill Medical College of Cornell University; and George R. Seage III and Milton C. Weinstein of Harvard School of Public Health.

Citation: Ann Intern Med. 145, 797-806 (December 5, 2006)

Yale University

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.